Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

HHS Adds New Anthrax Countermeasures to Stockpile

by Global Biodefense Staff
November 13, 2015
Bacillus anthracis mishap

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) this week announced it will add two types of anthrax antitoxin drugs to the Strategic National Stockpile (SNS) as options to treat inhalational anthrax.

ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will fund these purchases under Project BioShield, the chief mechanism through which the U.S. government supports the advanced development and procurement of new medical countermeasures – drugs, vaccines, diagnostics, and medical supplies – to protect the American public against chemical, biological, radiological and nuclear threats.

“Anthrax remains a bioterrorist threat, and the actions we are taking today will help protect our nation against that threat,” said Robin Robinson, Ph.D., Director of BARDA. “By expanding the treatment options available within the SNS, we can help meet the diverse needs of the American people in an anthrax-related emergency.”

Elusys Therapeutics – Anthim

A five-year, $44.9 million agreement with Elusys Therapeutics of Pine Brook, New Jersey, BARDA will support production and future delivery of Elusys’ anthrax antitoxin drug Anthim to the SNS. Anthim is a is a high-affinity monoclonal antibody (mAb) that binds to a key bacterial protein and reduces anthrax’s toxic effects. The antitoxin becomes the fourteenth product to be added to the SNS under Project BioShield since 2004.

Support for development of Anthim transitioned from early development with the National Institute of Allergy and Infectious Diseases (NIAID) to advanced development with BARDA in 2009. Elusys submitted a Biologics License Application for Anthim to the U.S. Food and Drug Administration (FDA) in March 2015, and BARDA continues to support the drug’s development under a separate research and development contract.

Prior to licensure, large-scale use of Anthim after an anthrax attack would require Emergency Use Authorization from FDA.

GlaxoSmithKline – Raxibacumab

In addition, through a continuing agreement with GlaxoSmithKline BARDA will fund the production and delivery of the anthrax antitoxin drug Raxibacumab to replace expiring doses in the SNS.

Raxibacumab is also a monoclonal antibody therapeutic to treat illness caused by anthrax. BARDA has funded advanced development and procurement of the drug under Project Bioshield since 2009 and in 2012 Raxibacumab became the first anthrax antitoxin to be approved by the FDA. Now, BARDA will provide $9.7 million to ensure a continued supply of Raxibacumab to the SNS through 2019.

Source: HHS, adapted.

Tags: AnthraxAntitoxinsASPRAwardsBARDABioterrorismEmergency Use AuthorizationHHSStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC